Hans Ehrencrona
41 – 50 of 81
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2015
-
Mark
FANCM c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor.
(
- Contribution to journal › Article
-
Mark
Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia.
(
- Contribution to journal › Scientific review
-
Mark
Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers.
(
- Contribution to journal › Article
-
Mark
Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006)
(
- Contribution to journal › Article
- 2014
-
Mark
RNA-seq identifies clinically relevant fusion genes in leukemia including a novel MEF2D/CSF1R fusion responsive to imatinib.
(
- Contribution to journal › Letter
-
Mark
DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers.
(
- Contribution to journal › Article
-
Mark
Functional implications of the p.Cys680Arg mutation in the MLH1 mismatch repair protein.
(
- Contribution to journal › Article
-
Mark
Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers
(
- Contribution to journal › Article
- 2013
-
Mark
Whole-genome-amplified DNA as a source for mutational analysis underestimates the frequency of mutations in pediatric acute myeloid leukemia
(
- Contribution to journal › Letter
-
Mark
Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients
(
- Contribution to journal › Article